Replies to post #183699 on Biotech Values

[GGBB]

Frontiers - i just registered for Investor Hub. I came across IHub while reviewing ACHN news/info. I read some of your posts once I registered. You seem very knowledgeable in the area of HCV as well as knowing a lot about ACHN's trials & other company's involved in HCV therapy. Do you have a clinical background in HCV? What is your background?

I came across some info which leads me to believe, ACHN-3422 is very similar to IDIX's Nuc. It seems there could be some IP issues b/w ACH-3422 and IDIX-21437. If MRK/IDIX claims there is an IP issue w/ ACHN's Nuc, then we could make an assumption, ACHN Phase 1 trial will be successful. Do you have any thoughts about IP issues b/w the two.

I believe one of your posts said ACHN-3422 and Solvadi were very close. I think ACHN used Solvadi as a "stand in." How valid is this…..

[DewDiligence]

ACHN—With the release of today’s monotherapy data (#msg-109273133), another HCV canard can be laid to rest: ACH-3422 is not a turbocharged version of Sovaldi.